Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period
Brief Summary: Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis \[MS\].

Secondary objectives were:

* To assess the effect of the two doses in comparison to interferon beta-1a on:

  * Frequency of relapses,
  * Fatigue,
  * Participant's satisfaction with treatment.
* To evaluate the safety and tolerability of the two doses in comparison to interferon beta-1a.

The study consisted of a core treatment period with a common end date defined as 48 weeks after randomization of the last participant, followed by an optional long-term extension treatment period until teriflunomide is commercially available in accordance with local regulations.


Options:
A: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
B: Arm Label: Placebo + IFN-β; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide), Drug: Interferon-β [IFN-β] | Arm Label: Teriflunomide 7 mg + IFN-β; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Interferon-β [IFN-β] | Arm Label: Teriflunomide 14 mg + IFN-β; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Interferon-β [IFN-β] | Arm Label: Placebo + GA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide), Drug: Glatiramer Acetate [GA] | Arm Label: Teriflunomide 7 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate [GA] | Arm Label: Teriflunomide 14 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate [GA] | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg + GA, Teriflunomide 14 mg + IFN-β, Teriflunomide 7 mg + GA, Teriflunomide 7 mg + IFN-β | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo + GA, Placebo + IFN-β | Intervention Type: DRUG; Name: Interferon-β [IFN-β]; Assigned to Arm(s): Placebo + IFN-β, Teriflunomide 14 mg + IFN-β, Teriflunomide 7 mg + IFN-β | Intervention Type: DRUG; Name: Glatiramer Acetate [GA]; Assigned to Arm(s): Placebo + GA, Teriflunomide 14 mg + GA, Teriflunomide 7 mg + GA
C: Arm Label: BG00012 plus placebo; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate, Drug: Placebo | Arm Label: BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Intervention Type: DRUG; Name: dimethyl fumarate; Assigned to Arm(s): BG00012, BG00012 plus placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 plus placebo
D: Arm Label: Placebo-Controlled Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Active Treatment Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Off Drug; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Active Treatment Phase: Laquinimod 1.2 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 1.2 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Placebo

Answer: A